Adding a third antibody, directed at a different target, to the usual tablet-and-antibody pairing added about eight months before follicular lymphoma progressed again.
A phase 3, double-blind, randomised, placebo-controlled trial at 210 centres in North America, Europe and the Asia-Pacific region. Adults with relapsed or refractory follicular lymphoma after at least one previous line were randomised 1 to 1 to up to twelve 28-day cycles of tafasitamab 12 mg per kilogram intravenously, or placebo, both with lenalidomide 20 mg daily on days 1 to 21 of cycles 1 to 12 and rituximab 375 mg per square metre. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population.
Between 16 April 2021 and 10 August 2023, 548 of 817 patients assessed were enrolled and randomised, 273 to tafasitamab and 275 to placebo; 299 (55 per cent) were male and 249 (45 per cent) female. Median progression-free survival by investigator was 22.4 months (95 per cent confidence interval 19.2 to not evaluable) with tafasitamab against 13.9 months (11.5 to 16.4) with placebo, a hazard ratio of 0.43 (0.32 to 0.58).
A new combination for relapsed or refractory follicular lymphoma that adds a CD19-directed antibody to the established lenalidomide and rituximab pairing. The United States label added the combination for relapsed or refractory follicular lymphoma in June 2025, and says it is not indicated for marginal zone lymphoma outside controlled clinical trials.
Shares A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa, Too many combinations to test, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares CD20, The Lancet, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma and the tag lymphoma-evidence.
Shares CD20, Lenalidomide, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Too many combinations to test, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma and the tag lymphoma-evidence.
Shares Laurie H. Sehn, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Laurie H. Sehn, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Marginal zone lymphoma, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/